Natalizumab Bests Fingolimod for Relapsing-Remitting MS Natalizumab Bests Fingolimod for Relapsing-Remitting MS

In a head-to-head comparison, natalizumab was superior to fingolimod for evidence of disease activity at 1 year for patients with active relapsing-remitting multiple sclerosis.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news